Oncobiologics (OTLK) Stock Price, News & Analysis

Company Overview

Oncobiologics, Inc. is a clinical‐stage biopharmaceutical company focused on the development of biosimilar therapies for oncology and autoimmune diseases. Founded in 2012 and headquartered in New Jersey, the company applies a tailored approach to protein engineering and cell line optimization to create high‐quality biosimilar candidates. Oncobiologics aims to provide more affordable therapeutic options by leveraging advanced biomanufacturing techniques and streamlined development pathways.

The company’s product pipeline includes several late‐stage biosimilar candidates designed to match reference biologics used in the treatment of cancer and chronic inflammatory disorders. Oncobiologics has established a strategic manufacturing partnership with a global contract development and manufacturing organization (CDMO), enabling scalable production of its lead candidates. The development program addresses key molecules with significant market demand, and the company has reported positive analytical and preclinical comparability results to date.

Oncobiologics serves a global footprint, targeting markets in North America, Europe and Asia-Pacific through a combination of in‐license agreements and commercialization partnerships. The company is working with regional distributors and pharmaceutical collaborators to navigate regulatory approvals and to facilitate market access upon approval. This geographic strategy is designed to accelerate product launches and to enable broad patient access to its biosimilar therapies.

The company is led by Executive Chairman Satish Hegde, Ph.D., and President & CEO Pratibha Sinha, who bring extensive experience in biopharmaceutical development and regulatory affairs. Supported by a leadership team of seasoned professionals in research, manufacturing and commercialization, Oncobiologics continues to advance its biosimilar portfolio through clinical trials and regulatory interactions. The company’s management emphasizes scientific rigor and cost‐effective development to meet the evolving needs of healthcare systems worldwide.

Key Stats

• Today's Range: $2.01 to $2.22
• 50-Day Range: $1.41 to $2.07
• 52-Week Range: $0.87 to $9.25
• Volume: 1.59 million shs
• Average Volume: 847,006 shs
• Market Capitalization: $69.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.60
• Consensus Rating: Moderate Buy

Oncobiologics Stock Analysis - MarketRank™

Oncobiologics scored higher than 47% of companies evaluated by MarketBeat, and ranked 705th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oncobiologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Oncobiologics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncobiologics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncobiologics is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncobiologics is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.29% of the float of Oncobiologics has been sold short.

Short Interest Ratio / Days to Cover

Oncobiologics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncobiologics has recently decreased by 20.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncobiologics does not currently pay a dividend.

Dividend Growth

Oncobiologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.29% of the float of Oncobiologics has been sold short.

Short Interest Ratio / Days to Cover

Oncobiologics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncobiologics has recently decreased by 20.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.08

News Sentiment

Oncobiologics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Oncobiologics this week, compared to 3 articles on an average week.

Search Interest

Only 7 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.

MarketBeat Follows

1 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncobiologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Oncobiologics is held by insiders.

Percentage Held by Institutions

Only 11.20% of the stock of Oncobiologics is held by institutions.

OTLK Stock Analysis - Frequently Asked Questions

How have OTLK shares performed this year?

Oncobiologics' stock was trading at $1.89 at the beginning of 2025. Since then, OTLK shares have increased by 9.5% and is now trading at $2.07.

How were Oncobiologics' earnings last quarter?

Oncobiologics, Inc. (NASDAQ:OTLK) announced its earnings results on Thursday, May, 15th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.15.

When did Oncobiologics' stock split?

Oncobiologics's stock reverse split on Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Oncobiologics?

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncobiologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OTLK
• CIK: 1649989
• Web: www.outlooktherapeutics.com
• Phone: (609) 619-3990
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncobiologics: $9.60
• High Price Target: $21.00
• Low Price Target: $3.00
• Potential Upside/Downside: +363.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -271.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.09) per share
• Price / Book: -0.67

Miscellaneous

• Outstanding Shares: 33,570,000
• Free Float: 31,957,000
• Market Cap: $69.49 million
• Optionable: Optionable
• Beta: 0.25